Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Radar on Market Access: Global Oncology Trends

Posted by Matt Breese on Jun 14, 2018

The field of oncology continues to see increasingly innovative treatments and increasingly higher prices, according to IQVIA Institute for Human Data Science’s recent report Global Oncology Trends: Innovation, Expansion and Disruption.

Murray Aitken, IQVIA senior vice president and executive director of the IQVIA Institute for Human Data Science, called 2018 "a banner year of new drugs being launched" during a May 22 media call. 2017 saw 14 cancer therapies launch, all of which targeted therapies and 11 with breakthrough therapy status.

Read More

Topics: Specialty, Industry Trends, Data & Analytics

Radar on Market Access: IngenioRx Drug Trend Report

Posted by Matt Breese on Jun 12, 2018

IngenioRx, the PBM being developed by Anthem, Inc., released a drug trend report on May 31 that illustrates how it plans to stand out in a rapidly changing PBM landscape: by analyzing and managing the cost of drugs prescribed to consumers through both their medical and pharmacy benefits, AIS Health reported.

"That’s a key differential in our report that you're not going to see anywhere else, and the numbers aren't going to match up and compare, because those competitors aren’t considering medical drug spend," says Colleen Haines, Anthem's president of clinical and specialty pharmacy.

Read More

Topics: Specialty, Industry Trends, Data & Analytics

Radar On Market Access: Value of Device-Gathered Data to Regulatory Agencies

Posted by Matt Breese on Jun 5, 2018

While physicians may be the obvious stakeholder to benefit from the data gathered from wearable and handheld drug-administration devices, regulatory bodies also are realizing their value, AIS Health reported.
 
In recent years, both FDA and the European Medicines Agency are warming to the use of real-world evidence (RWE) during the regulatory-approval process, according to John J. Doyle, senior vice president and general manager, real-world and analytic services, IQVIA.
 
Read More

Topics: Industry Trends, Data & Analytics

Radar On Market Access: Drug Cost Transparency Service

Posted by Matt Breese on May 24, 2018

Blue Shield of California has unveiled a program designed to show doctors lower-cost alternative medications and enable them to compare prices and make prescribing changes while meeting with patients in their offices, AIS Health reported.
 
The new Gemini Drug-Cost Transparency Service, which is developed by Gemini Health, LLC, taps into providers' existing electronic health record (EHR) systems. 
 
Read More

Topics: Data & Analytics, Payer

Radar On Market Access: Managed Care Strategies for Specialty Pharmaceuticals

Posted by Matt Breese on May 22, 2018

A survey by EMD Serono, Inc. revealed that managing oncology drugs and services remains the top challenge for health plans, tied with determining the value of specialty drugs and ensuring clinically appropriate use of specialty therapies.
 
Released at the end of April, the 14th edition of the EMD Serono Specialty Digest: Managed Care Strategies for Specialty Pharmaceuticals is based on survey responses from 59 commercial health plans representing more than 76 million covered lives. 
 
Read More

Topics: Industry Trends, Market Access, Data & Analytics

Radar On Market Access: Pharma's Role in Prior-Authorization Conflict

Posted by Matt Breese on May 8, 2018

Through funding of patient support programs and related hub services, pharma companies are playing a role in lessening the prior-authorization conflict between insurers and providers, AIS Health reported. .
 
Prior authorization (PA) is the exchange of patient health and medication information between a provider and a plan to make a coverage determination. Yet the most recent survey by the American Medical Association (AMA) showed that 92% of respondents agree that PAs delay therapy access, while 84% considering it a “high” burden. 
 
Read More

Topics: Industry Trends, Data & Analytics

Radar On Market Access: CVS’s Chronic Kidney Disease Program

Posted by Matt Breese on May 3, 2018

CVS Health Corp. recently unveiled an initiative aimed at improving the management of chronic kidney disease (CKD), a costly condition that affects millions in the United States, AIS Health reported.
 
The multipronged program incorporates, among other things, a focus on early disease identification and patient education. According to estimates from the Centers for Disease Control and Prevention, 30 million people in the U.S. have CKD. But many of them don’t realize it. 
 
Read More

Topics: Industry Trends, Data & Analytics, Payer

Radar On Market Access: Statin Gender Bias

Posted by Matt Breese on May 1, 2018

Women remain less likely than men to receive guideline-recommended, high-intensity statin therapy within 30 days after hospitalization for myocardial infarction (MI), AIS Health reported based on recent research published in the April 24 Journal of the American College of Cardiology.
 
The research looked at nearly 17,000 adults in the U.S. younger than 65 with commercial insurance and about 71,000 seniors ages 66-plus with Medicare coverage who were hospitalized for MI between 2014 and 2015. They found that 47% of women vs. 56% of men filled a high-intensity statin prescription within the 30-day post-hospitalization period. 
 
Read More

Topics: Industry Trends, Market Access, Data & Analytics, Payer

Radar on Market Access: Specialty Drug Spend

Posted by Matt Breese on Apr 26, 2018

The United States saw a 0.6% increase in net spending on medications to $324 billion last year, AIS Health reported based on IQVIA Institute for Human Data Science’s report.

Those numbers represent "the amount being received by pharmaceutical manufacturers net of rebates, off-invoice discounts and other concessions," said Murray Aitken, executive director of the institute. But on an invoice basis, total spending was $453 billion, according to Medicine Use and Spending in the U.S.: A Review of 2017 and Outlook to 2022.

Read More

Topics: Specialty, Industry Trends, Data & Analytics

Radar On Market Access: Managing Specialty Drug Costs as Top Employer Concern

Posted by Matt Breese on Apr 12, 2018

As costs for specialty drugs continue to rise, managing those costs remains employers’ top concern, according to a recent Pharmacy Benefit Management Institute (PBMI) study.
 
Since 2011, medical benefit spending has risen 55%, and “double-digit average specialty trend under the pharmacy benefit has been the norm since 2007,” notes PBMI’s 2018 Trends in Specialty Drug Benefits
 
Read More

Topics: Industry Trends, Data & Analytics, Payer